Cargando…

Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium

Asthma and chronic obstructive pulmonary disease (COPD) are major chronic conditions. It is possible to limit their impact by controlling symptoms, which limits exacerbations and worsening of the disease, by choosing the appropriate treatment and ensuring that the patient adheres to it. The main pur...

Descripción completa

Detalles Bibliográficos
Autores principales: Biset, Natacha, Lelubre, Mélanie, Pochet, Stéphanie, De Vriese, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386066/
https://www.ncbi.nlm.nih.gov/pubmed/37513942
http://dx.doi.org/10.3390/ph16071030
_version_ 1785081568520306688
author Biset, Natacha
Lelubre, Mélanie
Pochet, Stéphanie
De Vriese, Carine
author_facet Biset, Natacha
Lelubre, Mélanie
Pochet, Stéphanie
De Vriese, Carine
author_sort Biset, Natacha
collection PubMed
description Asthma and chronic obstructive pulmonary disease (COPD) are major chronic conditions. It is possible to limit their impact by controlling symptoms, which limits exacerbations and worsening of the disease, by choosing the appropriate treatment and ensuring that the patient adheres to it. The main purpose of this study was to assess medication adherence and persistence with inhaled medications for chronic treatment of asthma and COPD, as well as to evaluate the factors influencing this adherence. Medication adherence was measured from January 2013 to December 2016 using continuous multiple-interval measures of medication availability (CMA). Persistence was evaluated by treatment episodes (TE). We analyzed the influence of different factors on CMA such as sex, age, type of device, and the realization of the “new medicines service” (NMS), introduced in Belgium in October 2013 to support patients in adhering to their treatment. We also analyzed the consumption of these inhaled medications within the Belgian population and compared them with the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations. Medication adherence varied greatly between the different pharmacological classes: inhaled corticosteroids (ICS) alone or in combination with long-acting beta agonists (LABA) had the lowest medication adherence and persistence, while adherence was highest for the long-acting muscarinic antagonists (LAMA) and LABA/LAMA associations. The NMS seemed to have a positive impact on medication adherence, although few patients completed the two guidance interviews offered by the service. In addition, only a minority of the targeted patients took advantage of this new service.
format Online
Article
Text
id pubmed-10386066
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103860662023-07-30 Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium Biset, Natacha Lelubre, Mélanie Pochet, Stéphanie De Vriese, Carine Pharmaceuticals (Basel) Article Asthma and chronic obstructive pulmonary disease (COPD) are major chronic conditions. It is possible to limit their impact by controlling symptoms, which limits exacerbations and worsening of the disease, by choosing the appropriate treatment and ensuring that the patient adheres to it. The main purpose of this study was to assess medication adherence and persistence with inhaled medications for chronic treatment of asthma and COPD, as well as to evaluate the factors influencing this adherence. Medication adherence was measured from January 2013 to December 2016 using continuous multiple-interval measures of medication availability (CMA). Persistence was evaluated by treatment episodes (TE). We analyzed the influence of different factors on CMA such as sex, age, type of device, and the realization of the “new medicines service” (NMS), introduced in Belgium in October 2013 to support patients in adhering to their treatment. We also analyzed the consumption of these inhaled medications within the Belgian population and compared them with the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations. Medication adherence varied greatly between the different pharmacological classes: inhaled corticosteroids (ICS) alone or in combination with long-acting beta agonists (LABA) had the lowest medication adherence and persistence, while adherence was highest for the long-acting muscarinic antagonists (LAMA) and LABA/LAMA associations. The NMS seemed to have a positive impact on medication adherence, although few patients completed the two guidance interviews offered by the service. In addition, only a minority of the targeted patients took advantage of this new service. MDPI 2023-07-20 /pmc/articles/PMC10386066/ /pubmed/37513942 http://dx.doi.org/10.3390/ph16071030 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Biset, Natacha
Lelubre, Mélanie
Pochet, Stéphanie
De Vriese, Carine
Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title_full Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title_fullStr Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title_full_unstemmed Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title_short Asthma and COPD: Comparison with International Guidelines and Medication Adherence in Belgium
title_sort asthma and copd: comparison with international guidelines and medication adherence in belgium
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386066/
https://www.ncbi.nlm.nih.gov/pubmed/37513942
http://dx.doi.org/10.3390/ph16071030
work_keys_str_mv AT bisetnatacha asthmaandcopdcomparisonwithinternationalguidelinesandmedicationadherenceinbelgium
AT lelubremelanie asthmaandcopdcomparisonwithinternationalguidelinesandmedicationadherenceinbelgium
AT pochetstephanie asthmaandcopdcomparisonwithinternationalguidelinesandmedicationadherenceinbelgium
AT devriesecarine asthmaandcopdcomparisonwithinternationalguidelinesandmedicationadherenceinbelgium